Management of UTI with ESBL-Producing Organisms

Introduction to ESBL Organisms and Antibiotic Coverage

The American College of Physicians recommends carbapenems as the first-line treatment for patients with multiple infections including ESBL UTI, CAP, and infected PEG tube, with meropenem being the preferred agent due to its excellent coverage against ESBL-producing organisms and respiratory pathogens 1, 2
ESBL organisms are bacteria that produce enzymes capable of hydrolyzing extended-spectrum cephalosporins and monobactams, commonly including Enterobacteriaceae such as E. coli, Klebsiella species, and Proteus species 1

Antibiotics that effectively cover ESBL-producing organisms include carbapenems (meropenem, imipenem/cilastatin, ertapenem) - most reliable option 1, and newer β-lactam/β-lactamase inhibitor combinations (ceftazidime/avibactam, ceftolozane/tazobactam) 1, 3
For uncomplicated lower UTIs only: fosfomycin and nitrofurantoin (particularly for E. coli) are recommended 2

ESBL infections are associated with higher mortality, treatment failure, and healthcare costs compared to non-ESBL infections 4
The Infectious Diseases Society of America recommends standard precautions for all patients with ESBL-producing organisms, and contact precautions for patients with ESBL infections, particularly in healthcare settings 1
ESBL-producing organisms can spread between patients via healthcare workers' hands and contaminated equipment 4

For patients with multiple infection sites including ESBL UTI, CAP, and infected PEG tube, a carbapenem is the most appropriate choice 1, 2
Meropenem 1g IV three times daily provides optimal coverage for all three infection sites 1

The American College of Physicians recommends treatment duration of 7-14 days for ESBL UTI, 5-7 days for CAP, and 7-10 days for infected PEG tube 1
Monitor clinical response within 48-72 hours of initiating therapy, and follow up with blood cultures to document clearance for bacteremic infections 2